pitavastatin / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 50 Diseases   20 Trials   20 Trials   1121 News 


«12345678910111213...1415»
  • ||||||||||  Preclinical, Journal:  In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. (Pubmed Central) -  May 6, 2022   
    Inhibitory effects of asunaprevir, daclatasvir, grazoprevir, paritaprevir, simeprevir, and voxilaprevir, direct-acting antiviral (DAA) drugs for the treatment of chronic hepatitis C virus (HCV) infection, were evaluated in vitro against a range of clinically important drug transporters...Furthermore, we refined and developed static models to predict complex DDIs with several statins (pitavastatin, rosuvastatin, atorvastatin, and pravastatin) by mechanistically assessing differential inhibitory effects of perpetrator drugs on multiple transporters, such as organic anion transporting polypeptides (OATP1B), breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), organic anion transporter 3 (OAT3), and cytochrome P450 CYP3A enzyme, as they are known to contribute to absorption, distribution, metabolism and excretion (ADME) of above statins...Our studies suggest that mechanistic static model is a promising and useful tool to provide more accurate prediction of the risk and magnitude of DDIs with statins in early drug development and may help to improve the management of clinical DDIs for HCV drugs to ensure effective and safe HCV therapy. GRAPHICAL ABSTRACT.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Identification of potential functional variants and genes at 18q21.1 associated with the carcinogenesis of colorectal cancer. (Pubmed Central) -  Apr 12, 2022   
    Collectively, our data suggest that these functional variants at 18q21.1 are involved in the pathogenesis of CRC by modulating enhancer activity, and possibly LIPG expression, thus indicating a promising therapeutic target for CRC. The results of functional annotation in our investigation could also serve as an inventory for CRC susceptibility SNPs and offer guides for post-GWAS downstream functional studies.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Preclinical, Journal:  Development and validation of an HPLC method to be used for simultaneous detection and quantification of different statins after ex vivo skin diffusion studies. (Pubmed Central) -  Apr 9, 2022   
    A novel high performance liquid chromatography (HPLC) method was developed and validated to simultaneously analyse all statins currently available globally (atorvastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin)...The limit of detection (LOD) and limit of quantification (LOQ) values were found to be within the permissible criteria of ≤15% and ≤20%, respectively. Following an appropriate investigation of all the parameters for method validation, it was confirmed that the HPLC method was successfully validated and proven to be accurate to simultaneously quantify statins even in combination with other excipients used during the formulation of nano-emulsions and nano-emulgels.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Pitavastatin Induces Cancer Cell Apoptosis by Blocking Autophagy Flux. (Pubmed Central) -  Apr 8, 2022   
    Taken together, pitavastatin-mediated blockade of autophagy flux caused an accumulation of FOXO3a protein, thereby leading to the induction of PERK, ultimately causing CHOP-mediated apoptosis in cancer cells. Thus, the present study highlighted the additional molecular mechanism underlying the role of autophagy flux blockade in inducing ER stress, eventually leading to apoptosis by pitavastatin.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Retrospective data, Journal:  A Meta-Analysis of Statin Use and Risk of Hepatocellular Carcinoma. (Pubmed Central) -  Apr 7, 2022   
    In addition, the preventive effect of statins improved with the extension of follow-up time (odds ratio, 0.54 vs. 0.65). Our meta-analysis shows that the use of statins is associated with a lower risk of liver cancer.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Preclinical, Journal:  Pitavastatin activates mitophagy to protect EPC proliferation through a calcium-dependent CAMK1-PINK1 pathway in atherosclerotic mice. (Pubmed Central) -  Apr 5, 2022   
    Together, our findings describe a molecular mechanism of mitophagy activation, where mitochondrial calcium release promotes CAMK1 phosphorylation of threonine before phosphorylation of PINK1 at serine, which recruits PARK2 and phosphorylates its serine to activate mitophagy. Our results further account for the pleiotropic effects of statins on the cardiovascular system and provide a promising and potential therapeutic target for atherosclerosis.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Review, Journal:  Pitavastatin: Coronary Atherosclerotic Plaques Changes and Cardiovascular Prevention. (Pubmed Central) -  Mar 26, 2022   
    Moreover intravascular ultrasound have shown that pitavastatin induces favorable changes in plaque morphology, increasing the fibrous cap thickness, and decreasing both plaque and lipid volume indexes. Globally the efficacy of pitavastatin is greater or similar to other statins.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Comparative hepatic and intestinal efflux transport of statins. (Pubmed Central) -  Mar 25, 2022   
    Based on in vitro findings and protein abundance data, we conclude that BCRP, MRP3 and P-gp have a major impact in the efflux of various statins. Together with in vitro metabolism, uptake transport and clinical data, our findings are applicable for use in comparative systems pharmacology modelling of statins.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    PK/PD data, Journal:  Comparative hepatic and intestinal metabolism and pharmacodynamics of statins. (Pubmed Central) -  Mar 24, 2022   
    Significance Statement The present comparison of the in vitro metabolic and pharmacodynamic properties of atorvastatin, fluvastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin and their metabolites using unified methodology provides a strong basis for further application. Together with in vitro drug transporter and clinical data, our findings are applicable for use in comparative systems pharmacology modelling to predict the pharmacokinetics and pharmacological effects of statins at different dosages.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  An improved osseointegration of metal implants by pitavastatin loaded multilayer films with osteogenic and angiogenic properties. (Pubmed Central) -  Mar 15, 2022   
    The results of subcutaneous and femur implantation confirmed that locally released pitavastatin had potentially triggered a chain of biological events: mobilizing endogenous stem cells and ECs to the implant-bone interface, in turn facilitating coupled osteogenesis and angiogenesis, and eventually enhancing peri-implant osseointegration. This study enlarges the application scope of pitavastatin and provides an optional choice for developing a multifunctional bioactive coating on the surfaces of mental implants.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Drug repurposing screen reveals glioblastoma cell line susceptibility to statins (Section 24) -  Mar 9, 2022 - Abstract #AACR2022AACR_4052;    
    Statins appeared to be especially effective against glioblastoma lines and the effect could be linked to the direct or indirect inhibition of UBIAD1. In vitro validation of this finding is ongoing.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Statins Induce Actin Cytoskeleton Disassembly and an Apoptosis-Like Process in Acanthamoeba spp. (Pubmed Central) -  Feb 26, 2022   
    All the statins were able to cause DNA condensation, collapse in the mitochondrial membrane potential and a reduction in ATP level production, and disorganization of the total actin fibers in the cytoskeleton of all the evaluated Acanthamoeba strains. Our results showed that the tested statins were able to induce PCD compatible events in the treated amoebae, including chromatin condensation, collapse in the mitochondrial potential and ATP levels, cytoskeleton disassembly and ROS generation.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Pitavastatin Potentiates Beta2-Agonist Induced Bronchodilation (Room 2009/2011 (West Building, Level 2), Moscone Center) -  Feb 19, 2022 - Abstract #ATS2022ATS_6173;    
    The mechanism is independent of mevalonate, but may be mediated in part by the Rho-kinase pathway. These data provide strong support for the development of a novel combinatorial therapy for asthma.FUNDING: This work was supported by R01HL148715 (A.A.Z., R.K., X.A.)
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Review, Journal:  Pleiotropic Effects of Statins - What Is Their Clinical Significance? (Pubmed Central) -  Feb 9, 2022   
    They increase blood glucose with the exception of pitavastatin...However, pleiotropic effects of statins might play a role with respect to microvascular events. The difference in pleiotropic effects between the different statins might be a basis for a patient-oriented statin therapy.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    ASYMPTOMATIC SARS-CoV-2 INFECTION IS EXTREMELY COMMON AMONG PEOPLE WITH HIV ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1210;    
    REPRIEVE is an international primary atherosclerotic cardiovascular disease (ASCVD) prevention RCT of pitavastatin calcium vs. placebo among 7,770 PWH ages 40-75 on antiretroviral therapy (ART)...With Ab testing, we determined that 61% of COVID-19 infections were asymptomatic in the REPRIEVE cohort, similar to rates reported in the general population. HIV clinicians must remain vigilant about COVID-19 testing among PWH to assure that asymptomatic cases are identified.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    PROTEINURIA IS COMMON AMONG PEOPLE WITH HIV WITH CONTROLLED HIV VIREMIA ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_1158;    
    REPRIEVE is an international primary cardiovascular prevention RCT of pitavastatin calcium vs. placebo among 7,770 PWH ages 40-75 on antiretroviral therapy with eGFR ?60 mL/min/1.73mm2...Additionally, certain modifiable comorbidities, including HTN and smoking, were associated with abnormal values. In PWH with preserved eGFR, subclinical kidney disease can be identified using urine measures.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    NAFLD IS COMMON AND ASSOCIATED WITH CARDIOVASCULAR RISK IN REPRIEVE PARTICIPANTS ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_563;    
    The REPRIEVE Mechanistic substudy is embedded within an international primary CVD prevention RCT of pitavastatin calcium vs. placebo among 7,770 PWH ages 40-75 years on antiretroviral therapy (ART)...NAFLD was more prevalent with male sex, older age, non-black race, elevated BMI and metabolic syndrome. Elevated LpPLA-2 and hsCRP levels suggest a correlation between NAFLD and cardiovascular risk in PWH.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    GEOGRAPHICAL DIFFERENCES IN FUNCTIONAL IMPAIRMENT OF PEOPLE WITH HIV ([VIRTUAL]) -  Feb 7, 2022 - Abstract #CROI2022CROI_274;    
    REPRIEVE is a prospective, double-blind, randomized, placebo-controlled, multicenter, phase III primary cardiovascular prevention study of pitavastatin calcium vs placebo among PWH ages 45-75 on antiretroviral therapy (ART)...Over 1/3 of middle-aged and older PWH in a global cohort across diverse GBD regions demonstrate functional impairments, associated with numerous modifiable and non-modifiable factors. The associations between DASI and cardiometabolic risk suggest that a measure of functional status may improve risk prediction.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Journal:  Identification of foods that affect the anti-cancer activity of pitavastatin in cells. (Pubmed Central) -  Feb 4, 2022   
    However, extracts from beans, lettuce, oats, eggs and various nuts reduced the activity of pitavastatin. These data identified foods that patients could eat to potentially improve the outcome of clinical trials of pitavastatin in cancer.
  • ||||||||||  Livalo (pitavastatin) / Kowa, Eli Lilly
    Review, Journal:  A comprehensive review on the lipid and pleiotropic effects of pitavastatin. (Pubmed Central) -  Jan 29, 2022   
    The unique lipid and non-lipid effects of pitavastatin make this molecule a particularly interesting option for the management of different human diseases. In this review, we first summarized the lipid effects of pitavastatin and then strive to unravel the diverse pleiotropic effects of this molecule.